c11

Mito-apocynin (C11) is a mitochondria-targeting antioxidant that works by targeting and neutralizing reactive oxygen species (ROS) produced during cellular respiration. Triphenylphosphonium bromide has been found to be effective in preventing mitochondrial dysfunction, which is a major cause of the aging process and various diseases. It has anti-inflammatory, anti-apoptotic and antioxidant activities.

C-11 is a tubulin inhibitor and functions as an ADC cytotoxin, exhibiting cytotoxicity for carcinoma cell lines.

LysoPalloT-NH-amide-C3-ph-m-O-C11 is an agonist of the GPR174 receptor with an EC50 value of 34 nM.

Thalidomide-4-OH-C11-OH is a conjugate of an E3 ligase ligand and a linker (E3LigaseLigand-Linker Conjugates), comprising Thalidomide-4-OH and the corresponding linker. Thalidomide-4-OH-C11-OH acts as a Cereblon ligand to recruit CRBN protein and serves as a key intermediate for synthesizing complete PROTAC molecules, such as PROTAC GPX4 degrader-4.

Thalidomide-O-C11-acid is a synthetic E3 ligase ligand-linker conjugate, featuring a cereblon ligand derived from Thalidomide and a single linker, and is utilized in the synthesis of PROTAC [Proteolysis Targeting Chimeras].

Pomalidomide-C11-NH2 is a derivative of pomalidomide that acts as a ligand for the E3 ubiquitin ligase cereblon (CRBN) and is used to recruit cereblon protein. Pomalidomide-C11-NH2 can be attached via a linker to a protein ligand, forming a PROTAC.

Thalidomide-O-amido-C11-COOH (Compound IMiD acid 1) is a compound that acts as an E3 ligase ligand and linker for the CRBN (Cereblon) conjugate. This compound is useful in synthesizing PROTACs targeting the degradation of DOT1L.

STING agonist C11 is an agonist of the stimulator of interferon genes (STING) pathway.1 It induces secretion of type I IFN from THF and MM6 cells when used at a concentration of 50 μM. STING agonist C11 induces phosphorylation of IFN regulatory factor 3 (IRF3) and increases expression of IFIT1 and viperin, but not IL-1β, IL-6, or IL-8 in THF cells in a STING-dependent manner. It reduces viral titers of chikungunya, Venezuelan equine encephalitis, o'nyong-nyong, Mayaro, and Ross River viruses grown in THF cells (EC90s = 16.44, 16.7, 18.84, 25.19, and 22.57 μM, respectively), an effect that is dependent on the presence of STING and the IFN-α/β receptor (IFNAR).References1. Gall, B., Pryke, K., Abraham, J., et al. Emerging alphaviruses are sensitive to cellular states induced by a novel small-molecule agonist of the STING pathway. J. Virol. 92(6), e01913-01917 (2018). STING agonist C11 is an agonist of the stimulator of interferon genes (STING) pathway.1 It induces secretion of type I IFN from THF and MM6 cells when used at a concentration of 50 μM. STING agonist C11 induces phosphorylation of IFN regulatory factor 3 (IRF3) and increases expression of IFIT1 and viperin, but not IL-1β, IL-6, or IL-8 in THF cells in a STING-dependent manner. It reduces viral titers of chikungunya, Venezuelan equine encephalitis, o'nyong-nyong, Mayaro, and Ross River viruses grown in THF cells (EC90s = 16.44, 16.7, 18.84, 25.19, and 22.57 μM, respectively), an effect that is dependent on the presence of STING and the IFN-α/β receptor (IFNAR). References1. Gall, B., Pryke, K., Abraham, J., et al. Emerging alphaviruses are sensitive to cellular states induced by a novel small-molecule agonist of the STING pathway. J. Virol. 92(6), e01913-01917 (2018).

IRES-C11 is a specific inhibitor of translation that targets the internal ribosome entry site (IRES) of the c-MYC gene. It functions by blocking the interaction between heterogeneous nuclear ribonucleoprotein A1, a trans-acting factor required for c-MYC IRES activity, and its corresponding IRES. Notably, IRES-C11 does not inhibit the IRES activity of BAG-1, XIAP, and p53.

Thalidomide-5-O-C11-NH2 hydrochloride, a thalidomide-derived cereblon ligand, facilitates the recruitment of CRBN protein and can be conjugated to a protein ligand via a linker to synthesize PROTACs [1].

Thalidomide-4-O-C11-NH2 hydrochloride is a thalidomide-based cereblon ligand for CRBN protein recruitment, capable of conjugation to a protein ligand via a linker to create PROTACs [1].

Pomalidomide-C11-NH2 hydrochloride is a cereblon (CRBN) ligand derived from Pomalidomide used to recruit the CRBN protein. This compound can be conjugated with a linker to the protein ligand to assemble a PROTAC [1].

Pomalidomide-5-C11-NH2 hydrochloride is a Pomalidomide-derived cereblon (CRBN) ligand that facilitates CRBN protein recruitment and can be conjugated to a protein ligand via a linker to create a PROTAC [1].

C11-PEG4-alcohol is a linker composed of an aliphatic carbon chain and a PEG chain. The hydrophilic PEG chain enhances the compound's solubility in aqueous media. The hydroxyl group can be further derivatized or replaced with other reactive functional groups.

C11-PEG9-alcohol is a linker consisting of an aliphatic carbon chain and a PEG chain. The hydrophilic PEG chain enhances the compound's solubility in aqueous media. The hydroxyl group can be further derivatized or replaced with other reactive functional groups.

C11-PEG6-alcohol (3,6,9,12,15-Pentaoxahexacosan-1-ol) is a linker featuring an aliphatic carbon chain and a PEG chain. The hydrophilic PEG chain enhances the compound's solubility in aqueous media. The hydroxyl group can be further derivatized or replaced with other reactive functional groups.

(S)-Desmethyl-NNC112 ((+)-Desmethyl-NNC112) is a selective PET radioligand that binds to D-dopamine receptors.

BFC1108 targets Bcl-2 and converts it to a pro-apoptotic protein, inhibits the growth of triple-negative breast cancer xenografts with high Bcl-2 expression, inhibits breast cancer lung metastasis, and induces apoptosis of Bcl-2-expressing cancer cells.

NSC117079 is a novel PHLPP1/2 (Pleckstrin homology domain and leucine rich repeat protein phosphatase) inhibitor that activates neuronal AKT and ameliorates staurosporine-induced cell death in neurons.

EC1169 is a targeted tubulysin conjugate that utilizes EC1167 as its linker. This compound shows promise in the treatment of recurrent metastatic, castration-resistant prostate cancer (MCRPC)[1].

AC1115 is a potent and selective next-generation antiviral compound targeting SARS-CoV-2 Mpro and the host lysosomal cysteine protease cathepsin L (CTSL), demonstrating high antiviral activity.

HDAC11-IN-1 (Compound 14-NC6OH) is a macrocyclic inhibitor that selectively targets HDAC11 with a Ki of 40 nM. It demonstrates effective cell permeability and suppresses the expression of YAP1 and SOX2.

HDAC11-IN-2 (compound B6) is a highly selective inhibitor of Histone Deacetylase 11 (HDAC11). It demonstrates IC50 values of 51.1 ×10^-3 μM for HDAC11 and 5 μM for HDAC8. HDAC11-IN-2 reduces de novo lipogenesis (DNL) and enhances fatty acid oxidation, which alleviates hepatic lipid accumulation and pathological symptoms in MASLD mice. By inhibiting HDAC11, HDAC11-IN-2 enhances the phosphorylation of AMPKα1 at the Thr172 site, thereby modulating de novo lipogenesis and fatty acid oxidation in the liver.

HDAC11-IN-3 (Compound A9) is a selective inhibitor of HDAC11, exhibiting an IC50 value of 4.1 nM. It demonstrates inhibitory effects on U937 and OCI-AML2 acute myeloid leukemia (AML) cell lines with an IC50 of 10 μM. This compound shows significant anti-AML activity by inducing apoptosis, cell cycle arrest, and differentiation. HDAC11-IN-3 upregulates the iron transport proteins transferrin (TF) and transferrin receptor (TFRC), and activates the p62-Keap1-Nrf2-HMOX1 pathway, which collectively increases intracellular iron levels and induces ferroptosis in AML cells. HDAC11-IN-3 can be utilized for AML research either alone or in combination with Cytarabine.